Acute Mesenteric Ischemia

Acute mesenteric ischemia (AMI) is a life-threatening vascular emergency caused by sudden reduction in mesenteric blood flow, leading to bowel ischemia and infarction if untreated [^[5]D5,^[7]D5]. The condition carries a hospital mortality of 64% and 1-year mortality of 74% in population-based series ^[2]B2b.

Also Called / Synonyms

• Acute mesenteric ischemia (AMI)
• Mesenteric infarction
• Acute bowel ischemia
• Nonocclusive mesenteric ischemia (NOMI) - a subtype

Classification by Etiology

AMI is classified into four subtypes based on the mechanism of blood flow compromise. The distinction is critical because management priorities differ: arterial occlusive disease requires urgent revascularization, venous thrombosis benefits from anticoagulation, and NOMI is managed with vasodilators and hemodynamic optimization.

Surgical Nomenclature

The term "surgical lesion" refers to the segment of visibly necrotic or irreversibly ischemic bowel found at laparotomy. In operative series, 81.5% of patients undergoing exploration have transmural infarction or necrosis ^[6]B3b. The extent of bowel involvement (localized vs. pan-intestinal) determines the resectability and prognosis. The surgical nomenclature distinguishes between:

• Segmental ischemia - limited to a single loop or segment; amenable to resection.
• Pan-intestinal ischemia - involvement of the entire small bowel and often the right colon; considered unsalvageable and prompts palliation.

Early diagnosis and revascularization are critical to improving outcomes ^[7]D5. The classification of AMI into these subtypes, combined with the intraoperative finding of bowel viability, forms the basis for operative decision-making discussed in subsequent sections.

Pearl: The classification of AMI into arterial occlusive, venous, and non-occlusive subtypes guides initial management strategy, with arterial occlusive being the most common subtype (approximately 58% of cases) ^[6]B3b.

The classification above stratifies AMI by the vascular territory and mechanism of occlusion; downstream of each occlusive event, however, the tissue injury proceeds through a shared molecular and cellular cascade that determines the surgical lesion.

Regardless of the initiating insult, arterial embolus or thrombosis, mesenteric venous thrombosis, nonocclusive hypoperfusion, or strangulating obstruction, the final common pathway is a sudden reduction in intestinal blood flow below the metabolic demand of the bowel ^[22]D5. The sequence of injury is predictable and time-dependent:

1. Mucosal hypoxia - The intestinal mucosa, with its high oxygen requirement, is the most vulnerable layer. Within minutes of flow cessation, adenosine triphosphate (ATP) depletion impairs the Na+/K+ pump, leading to cellular edema and loss of tight junction integrity.

2. Loss of barrier function - Disruption of the mucosal barrier allows translocation of luminal bacteria and endotoxins into the portal and systemic circulation, triggering a local and then systemic inflammatory response.

3. Inflammatory amplification - Ischemic enterocytes release damage-associated molecular patterns (DAMPs) that activate toll-like receptors on resident macrophages, driving secretion of proinflammatory cytokines (TNF-α, IL-1, IL-6) and recruitment of neutrophils ^[23]D5. Neutrophil adhesion to the microvascular endothelium, mediated by upregulation of P-selectin and ICAM-1, further compromises capillary flow and amplifies tissue injury.

4. Smooth muscle damage - As ischemia deepens, the intestinal smooth muscle layers become involved. Smooth muscle protein 22 (SM22), a cytoskeletal protein abundant in intestinal smooth muscle, is released into the circulation when transmural ischemia is present, serving as a plasma biomarker of irreversible injury ^[11]B3b.

5. Transmural necrosis - Once all layers of the bowel wall are infarcted, the process is irreversible. The transition from reversible ischemia to transmural necrosis occurs over a time-critical window that varies with the underlying cause and collateral circulation; arterial occlusive AMI progresses most rapidly ^{[9]A1c[10]A1c}. The surgical lesion, full-thickness necrosis, is the point of no return at which resection is mandatory.

6. Reperfusion injury - Restoration of blood flow, while essential for salvage, paradoxically exacerbates tissue damage. Neutrophils already primed in the ischemic bed release reactive oxygen species, proteases, and proinflammatory mediators upon reoxygenation, causing further endothelial injury and capillary leak ^[23]D5. This reperfusion syndrome can propagate systemic inflammation and precipitate remote organ injury, particularly acute lung injury, which occurs in nearly 30% of patients with AMI and contributes significantly to mortality ^[23]D5.

Mechanism Flowchart

The Surgical Lesion

Transmural intestinal necrosis is the critical endpoint that mandates operative intervention. The diagnosis is retrospectively confirmed at laparotomy by the presence of nonviable bowel, dark, edematous, noncontractile segments with absent arterial pulsations. Several independent predictors of transmural necrosis can be identified preoperatively and are useful for triage:

• Mesenteric arterial occlusion (OR 26.5) ^[17]C4
• Leukocytosis (OR 1.3 per unit increase) ^[17]C4
• Metabolic acidosis (OR 3.8) ^[17]C4
• Free intraperitoneal fluid on CT (OR 4.21) ^[17]C4
• Combined portal vein and SMV thrombosis (OR 3.4) ^[17]C4
• Bowel wall thinning (DOR 13.1; specificity 98%) ^[13]A1a
• Decreased or absent bowel wall enhancement (DOR 5.77) ^[13]A1a
• Pneumatosis intestinalis (DOR 5.78) ^[13]A1a
• Porto-mesenteric venous gas (DOR 5.36; specificity 95%) ^[13]A1a

Radiological predictors differ by etiology: decreased bowel wall enhancement and bowel dilation are predictive of transmural necrosis in venous occlusive AMI but not in arterial occlusive AMI, reflecting the distinct pathophysiologies of congestion versus inflow failure ^[13]A1a.

The presence of these features should lower the threshold for immediate laparotomy, as they indicate that the window for bowel salvage has closed.

Pearl: The transition from mucosal ischemia to transmural necrosis can be silent, absence of peritonitis does not rule out transmural infarction; look for the combination of metabolic acidosis, leukocytosis, and CT signs of bowel wall thinning or pneumatosis to trigger timely surgical exploration ^{[13]A1a[17]C4}.

From the pathophysiologic substrate of vascular occlusion and hypoperfusion, the clinical epidemiology of acute mesenteric ischemia (AMI) emerges as a disease of the elderly and the comorbid. The population-based annual incidence is 8.7 per 100,000), with a median age of 79 years (range 32-104) and a female predominance of 57% ^[2]B2b. AMI accounts for 0.09-0.2% of all acute surgical admissions ^{[9]A1c[10]A1c}. Hospital mortality reaches 64%, and 1‑year all‑cause mortality 74%; among patients receiving active treatment (revascularization and/or resection), hospital mortality falls to 32% and 1‑year mortality to 51% ^[2]B2b. In patients discharged alive, 1‑year survival is 81.3%, with satisfactory quality of life in most survivors ^[36]B2b.

Demographics and Temporal Trends

Incidence rises sharply with age, reflecting the accumulation of atherosclerotic risk factors and atrial fibrillation ^{[2]B2b[12]B3b}. No clear sex difference in incidence exists beyond the female majority in the Estonian cohort ^[2]B2b. Temporal trends are not well characterized, but the proportion of embolic cases may be declining relative to thrombotic causes as anticoagulation for atrial fibrillation becomes more widespread ^{[2]B2b[34]B2b}.

Risk Factors

Risk factors for AMI cluster into three domains: cardiovascular comorbidities, prothrombotic states, and acute precipitants. The strongest independent associations are summarized in the table below.

Additional risk factors for transmural bowel necrosis include mesenteric arterial occlusion (OR 26.5), leukocytosis (OR 1.3), acidosis (OR 3.8), free intraperitoneal fluid (OR 4.21), and combined portal vein and superior mesenteric vein thrombosis (OR 3.4) ^[17]C4. Hemorrhagic ascites , peritonitis, intestinal diameter >2.35 cm, and serum creatinine >95 μmol/L independently predict irreversible transmural necrosis ^[29]B2b.

Modifiable Lifestyle Factors

In the only prospective cohort study to date, current smoking tripled the risk of AMI (aHR 3.02), and high alcohol consumption more than doubled it (aHR 2.53) ^[33]B2b. High physical activity (25.1-50.0 MET‑h/week) was protective (aHR 0.51). Diet quality and individual dietary components showed no significant association ^[33]B2b.

Special Populations

AMI can occur in children and young adults without classic risk factors. Case reports describe superior mesenteric vein thrombosis in a 15‑year‑old ^[31]C4 and nonocclusive mesenteric ischemia secondary to Mycoplasma pneumoniae pneumonia in a 6‑year‑old ^[32]C4. Morbid obesity, especially after bariatric surgery, may predispose to mesenteric venous thrombosis ^[19]C4.

Pearl: Smoking cessation and moderate alcohol intake are the only modifiable lifestyle factors proven to reduce AMI risk; physical activity is protective, while diet quality appears irrelevant ^[33]B2b.

These epidemiological patterns set the stage for the clinical encounter, where the history and examination must rapidly identify patients at risk of acute mesenteric ischemia (AMI).

Presenting Symptoms

The hallmark of AMI is severe abdominal pain that is sudden in onset (OR 20) and requires morphine (OR 6) ^[12]B3b. In a cross‑sectional study, 88% of AMI patients had one or both features versus 28% of controls (p < 0.001) ^[12]B3b. The pain is typically periumbilical or diffuse, reflecting midgut ischemia, and is described as “out of proportion” to the tenderness elicited on palpation. Associated symptoms include:

• Nausea and vomiting (often bilious)
• Diarrhea, which may become bloody (hematochezia)
• Anorexia and abdominal distension
• Late‑stage: altered mental status, dyspnea, or shock

The timeline is compressed: symptoms progress over hours to days, with transmural necrosis possible within 6-12 hours of complete arterial occlusion ^[9]A1c. A delay >48 hours from symptom onset to revascularization is associated with a perioperative mortality of 39% versus 14% and a higher rate of short bowel syndrome (39% vs 12%, p = 0.002) ^[34]B2b.

Abdominal and Systemic Examination Findings

Pain out of proportion to tenderness is the classic dissociation. Early in the course, the abdomen may be soft with minimal guarding; bowel sounds may be normal or hyperactive. As ischemia progresses to transmural necrosis, peritoneal signs emerge:

• Guarding and rigidity (late, indicating peritonitis)
• Absent bowel sounds (paralytic ileus)
• Abdominal distension (due to ileus or free fluid)
• Hypotension, tachycardia, fever (systemic inflammatory response)
• Metabolic acidosis ( lactic acidosis from anaerobic metabolism)

The absence of peritoneal signs does not rule out AMI, up to one‑third of patients with transmural necrosis lack overt peritonitis at presentation ^[17]C4. Independent predictors of transmural necrosis include mesenteric arterial occlusion (OR 26.5), leukocytosis (OR 1.3 per unit), acidosis (OR 3.8), free intraperitoneal fluid (OR 4.21), and combined portal vein/SMV thrombosis (OR 3.4) ^[17]C4.

Phenotypic Variants

Frequency estimates are derived from guideline reviews ^{[9]A1c[10]A1c}. Venous AMI accounted for 35% of cases in one series ^[12]B3b, but this varies by population.

Red Flags

• Sudden‑onset, morphine‑requiring abdominal pain, the strongest independent predictor (AUC 0.84) ^[12]B3b
• Peritoneal signs (guarding, rigidity, rebound), mandate urgent surgical evaluation
• Metabolic acidosis (pH < 7.25, base deficit > -8 mmol/L), suggests transmural necrosis ^[17]C4
• Elevated lactate (> 2 mmol/L), sensitive but not specific; rising lactate despite resuscitation is ominous
• Hemodynamic instability (hypotension, tachycardia), indicates advanced disease
• Pneumatosis intestinalis or portal venous gas on CT, associated with 69% mortality when ischemia is confirmed ^[42]B2a

Any red flag should prompt immediate multiphasic CT angiography (CTA) and surgical consultation ^{[9]A1c[10]A1c}.

Atypical Presentations

• Elderly patients may present with vague abdominal pain, confusion, or anorexia without classic pain ^[9]A1c.
• Children are rare; a 15‑year‑old boy with SMV thrombosis presented with hypotension and acidosis but no risk factors ^[31]C4.
• Post‑operative patients (e.g., after bariatric surgery) may have pain attributed to the procedure, delaying diagnosis ^[19]C4.
• ICU patients with NOMI often cannot report pain; signs include unexplained hypotension, rising lactate, or new organ dysfunction ^[37]C4.
• Patients with altered mental status (e.g., dementia, sedation) may only exhibit hemodynamic instability or distension.

In all atypical presentations, a high index of suspicion and low threshold for CTA are essential.

Pearl: The combination of sudden‑onset pain and need for morphine has an AUC of 0.84 for AMI ^[12]B3b; when both are present, proceed directly to multiphasic CTA without waiting for laboratory results.

The clinical suspicion raised by sudden-onset, morphine -requiring abdominal pain in an elderly patient with cardiovascular risk factors must be confirmed by CT angiography (CTA) without delay ^[12]B3b. The diagnostic workup proceeds from imaging to laboratory confirmation and risk stratification, with the goal of identifying both the presence of ischemia and the likelihood of transmural necrosis.

Imaging

CTA is the gold-standard diagnostic test for AMI. A 2025 meta-analysis of 81 studies reported a pooled sensitivity of 92.0% and specificity of 98.8% for CTA, compared with 75.8% and 90.5% for other CT protocols ^[41]A1a. The examination must include arterial and venous phase images to distinguish occlusive from non-occlusive causes ^{[9]A1c[10]A1c}.

Key CTA findings vary by subtype:

• Arterial occlusive AMI: Filling defect in the superior mesenteric artery (SMA) or celiac trunk, often with absent bowel wall enhancement distal to the occlusion ^[22]D5.
• Venous AMI: Thrombus in the superior mesenteric vein (SMV) or portal vein, with bowel wall thickening and mesenteric edema ^[22]D5.
• Non-occlusive mesenteric ischemia (NOMI): Diffuse vasospasm of mesenteric vessels, often with segmental bowel wall thinning and lack of enhancement ^[40]C4.

Among non-vascular features, absent or reduced bowel wall enhancement provides the best prognostic value for transmural necrosis (sensitivity 57.9%, specificity 90.1%) ^[41]A1a. Pneumatosis intestinalis and portal venous gas, historically associated with 70% mortality, now carry an overall mortality of 31%; however, when ischemia is confirmed, mortality rises to 69% ^[42]B2a. These findings must be interpreted in the full clinical context.

Table 1. Diagnostic Performance of CT Protocols for AMI

Laboratory Studies

No single biomarker is diagnostic, but several support the clinical picture. A four-parameter scoring system derived from 106 patients assigns points for elevated white blood cell count (OR 16.11), red cell distribution width (OR 27.65), mean platelet volume (OR 16.06), and D-dimer (OR 42.91) ^[39]B2b. A cutoff score of ≥4 yields sensitivity 97.8%, specificity 91.8%, positive predictive value 89.8%, and negative predictive value 98.2% ^[39]B2b. This score can be calculated at the bedside from routine labs.

Other laboratory markers include:

• Lactate and base deficit: Elevated in advanced ischemia but lack specificity; normal values do not exclude AMI ^{[9]A1c[10]A1c}.
• C-reactive protein and procalcitonin: Higher in AMI than other acute abdomen, but not independently diagnostic ^[12]B3b.
• SM22: A smooth muscle protein released with transmural injury; early data show significantly higher levels in transmural vs mucosal ischemia ^[11]B3b. Not yet clinically available.
• Hypoxia-inducible factor 1-alpha and adrenomedullin: Elevated in animal models, with adrenomedullin rising earlier ^[44]D5; clinical utility unproven.

Predictors of Transmural Necrosis

Identifying irreversible bowel necrosis is critical for surgical timing. Independent predictors from a cohort of 101 patients include ^[17]C4:

• Mesenteric arterial occlusion (OR 26.5, p=0.02)
• Leukocytosis (OR 1.3, p<0.0001)
• Acidosis (OR 3.8, p=0.04)
• Free intraperitoneal fluid (OR 4.21, p=0.005)
• Combined portal vein and SMV thrombosis (OR 3.4, p=0.026)

A nomogram incorporating age, ASA score, pneumatosis intestinalis, and dilated bowel loops predicts intestinal necrosis upon radiological suspicion with a C-index of 0.726 ^[26]B2b.

Differential Diagnosis

AMI must be distinguished from other causes of acute abdomen, including perforated viscus, acute pancreatitis, bowel obstruction, diverticulitis , and mesenteric adenitis. The presence of sudden-onset, morphine-requiring pain in a patient with atrial fibrillation , recent myocardial infarction, or hypercoagulable state strongly favors AMI ^{[12]B3b[47]B2b}. CTA reliably differentiates these entities.

Diagnostic Algorithm

Step 1: Clinical suspicion triggers immediate CTA. Step 2: Positive CTA confirms AMI; negative CTA with high suspicion may warrant repeat imaging or angiography ^[40]C4. Step 3: Assess for predictors of transmural necrosis (arterial occlusion, acidosis, free fluid, pneumatosis). Step 4: High-risk patients proceed directly to surgery; low-risk patients may undergo revascularization with second-look laparotomy ^{[9]A1c[10]A1c}.

Intraoperative Assessment

When laparotomy is performed, objective assessment of bowel viability guides resection margins. Diffuse reflectance spectroscopy (DRS) measures tissue oxygen saturation; a ΔStO₂ threshold of 12.3 ± 2.6% correlates with a Chiu score of 2, indicating need for resection ^[48]B2b. Bedside laparoscopy can be used in NOMI patients to avoid non-therapeutic laparotomy, with a reported 30% mortality in resected patients vs 11% in those managed without resection ^[37]C4.

Pearl: The combination of sudden-onset abdominal pain requiring morphine and a D-dimer > 0.5 mg/L should prompt immediate CTA; a diagnostic score ≥4 (WBC, RDW, MPV, D-dimer) has 97.8% sensitivity for AMI ^[39]B2b.

Once the diagnosis of acute mesenteric ischemia (AMI) is established, the next critical step is to stratify the severity of ischemic injury and estimate the operative risk to guide timely intervention. Several validated scoring systems and risk indices convert the clinical picture into a numeric trigger for operation and predict perioperative mortality.

Diagnostic Scoring Systems for Operative Trigger

The Wang score, derived from 106 patients with suspected AMI, combines four easily available hematological parameters: white blood cell count (OR 16.11), red cell distribution width (OR 27.65), mean platelet volume (OR 16.06), and D-dimer (OR 42.91) ^[39]B2b. A cutoff score of 4 best identifies patients with AMI, with a sensitivity of 97.8%, specificity of 91.8%, positive predictive value of 89.8%, and negative predictive value of 98.2% ^[39]B2b. This score can be applied at the bedside to differentiate AMI from other acute abdominal conditions, thereby prompting earlier operative consultation.

For predicting transmural bowel necrosis, the definitive indication for bowel resection, the Emile-Khan Score, proposed from a systematic review of 963 patients, incorporates eight clinical, seven biochemical, and six radiologic predictors ^[50]A1a. Pooled odds ratios were available for eight factors reported by ≥2 studies, providing a weighted prognostic tool that justifies urgent laparotomy before irreversible necrosis supervenes ^[50]A1a.

Operative Risk Indices for Perioperative Mortality

The Haga score, developed from a retrospective cohort of 110 patients across 26 Japanese hospitals, uses three independent predictors of in-hospital mortality: electrocardiogram scale (OR 1.7 per unit), shock index (OR 11), and age score ^[57]B3b. The simplified scoring system (S) categorizes patients into three risk strata: S ≤2 (mortality 19%), S of 3 or 4 (37%), and S ≥5 (91%) ^[57]B3b. The area under the receiver-operating characteristic curve was 0.82, indicating good discriminatory ability for mortality prediction ^[57]B3b.

Among patients with AMI who require damage control surgery (DCS), the presence of ≥1 DCS criterion, hypotension (<70 mmHg), hypothermia (<35 °C), acidosis (pH < 7.25), coagulopathy (INR ≥ 1.7), or massive transfusion (>5 RBC), stratifies operative mortality ^[16]C4. In a cohort of 68 AMI patients treated with DCS, mortality was 24% with one criterion, 48% with two, and 62% with ≥3 criteria ^[16]C4. On multivariate analysis, age and INR ≥ 1.7 were independent predictors of death ^[16]C4.

Additional univariate predictors of early death after revascularization include elevated SVS comorbidity score, congestive heart failure, and chronic kidney disease, while advanced ischemia with bowel infarction at presentation portends poor outcome ^[53]B3b.

Novel Biomarkers in Risk Stratification

Smooth muscle protein 22 kDa (SM22) is a plasma biomarker specifically released from intestinal smooth muscle during transmural ischemia. Levels rise significantly after 4 hours of ischemia in animal models and correlate with the histological degree of smooth muscle damage ^[11]B3b. In human pilot data, patients with transmural intestinal ischemia had significantly higher plasma SM22 than those with mucosal-only ischemia or other acute abdominal diseases ^[11]B3b. Although not yet integrated into a formal score, SM22 may serve as a future tool for quantifying the severity of ischemic injury.

Pearl: Use the Wang score (cutoff 4) to rapidly confirm AMI in the emergency ward, and the Haga score (S ≥ 5) to flag patients with > predicted mortality who may benefit from aggressive DCS and early family discussion.

Once severity and risk are stratified, the clock starts on a resuscitation-to-source-control pathway that must be executed in parallel, not in sequence. Every hour of delay in any of the four pillars, fluid resuscitation, antibiotics , anticoagulation, and revascularization, independently worsens survival ^{[10]A1c[64]B3b}.

Step 1: Initial Assessment and Triage

Classify the patient immediately into one of two tracks:

• Peritonitis or shock (lactate > 2 mmol/L, vasopressor requirement, SAPS II ≥ 62, hemoglobin ≤ 10.9 g/dL): admit to ICU or high-dependency unit. Enteral nutrition should be withheld in this group, the NUTRIREA2 post hoc analysis found that enteral nutrition was independently associated with AMI (OR not reported, but multivariate analysis with HR; hazard ratio not calculable) ^[58]B2b.
• No peritonitis, stable hemodynamics, lactate < 2 mmol/L: the patient may be managed on a monitored surgical ward, but with the same resuscitation pathway initiated immediately.

Step 2: Simultaneous Medical Resuscitation

Resuscitation: Begin aggressive fluid resuscitation with balanced crystalloids (e.g., lactated Ringer's) to restore intravascular volume. Target a mean arterial pressure ≥ 65 mm Hg. Add norepinephrine as the first-line vasopressor if fluid alone is insufficient; avoid dobutamine unless low cardiac output is documented, because dobutamine use was independently associated with AMI in the NUTRIREA2 cohort ^[58]B2b.

Antibiotics: Administer broad-spectrum intravenous antibiotics (e.g., piperacillin-tazobactam or carbapenem plus metronidazole ) to treat translocation and prevent progression to irreversible transmural intestinal necrosis (ITIN) ^[10]A1c. In a prospective cohort study (N=67), oral non-absorbable antibiotics (e.g., selective digestive decontamination) were independently associated with a decreased risk of ITIN (HR 0.16, 95%; p=0.01) ^[60]B2b. Consider adding oral antibiotics once the patient can tolerate them, although the evidence is from a single center.

Anticoagulation: Start therapeutic-dose anticoagulation (e.g., intravenous unfractionated heparin ) as soon as the diagnosis of AMI is suspected, regardless of the subtype or whether surgical intervention is planned. In an international multicenter study of 370 ICU patients, early full-dose anticoagulation was associated with improved 30-day survival (53.5% vs 41.7%, p=0.01; NNT = 8) and no increase in hemorrhagic complications ^[64]B3b. Survival benefit persisted at 90 days (p=0.02).

Step 3: Revascularization and Source Control

These two interventions, revascularization (endovascular or open) and/or bowel resection, were the only therapies associated with survival in the adjusted analysis ^[64]B3b. The choice between endovascular and open approaches, and the decision to perform a damage-control laparotomy versus primary anastomosis, are discussed in the next section. However, the principle is: revascularize first (if feasible) to restore blood flow to potentially ischemic bowel, then resect only non-viable tissue. The damage-control approach (bowel resection, temporary abdominal closure, and second-look laparotomy at 48 hours) reduces anastomotic dehiscence (5.3% vs 23.4%, p=0.03) and the need for ileostomy (2.6% vs 19.1%, p=0.03) compared with one-stage primary anastomosis, even in patients without sepsis ^[59]B2b.

Figure 1: Management algorithm for acute mesenteric ischemia (adapted from WSES guidelines ^[10]A1c and supporting evidence).

Step 4: Monitoring and Titration

• Serial lactate measurements every 6-12 hours; a rising or persistently elevated lactate despite resuscitation suggests ongoing ischemia and mandates surgical re-exploration ^[10]A1c.
• Hemodynamic monitoring : target MAP ≥ 65 mm Hg with norepinephrine, avoiding dobutamine unless specifically indicated ^[58]B2b.
• Abdominal examination: every 2-4 hours; new peritonitis or increasing abdominal distention is an indication for emergency laparotomy.
• Coagulation monitoring: aPTT every 6 hours initially, titrating heparin to a therapeutic range (1.5-2.5 times baseline).

Step 5: Transition to Definitive Management

Once the patient is hemodynamically stable and no further ischemia is evident, consider:

• Enteral nutrition: restart cautiously only after hemodynamic stability is assured and vasopressors are weaned. In patients requiring dobutamine or with SAPS II ≥ 62, enteral nutrition should be delayed ^[58]B2b.
• Transition to oral anticoagulation if long-term anticoagulation is indicated (e.g., for atrial fibrillation , thrombophilia) ^[63]C4.
• Definitive revascularization if a hybrid approach was used for initial stabilization.

The operative decision-making process, including the choice between open surgery, endovascular therapy, and hybrid approaches, is detailed in the following section.

What NOT to Do

• Do NOT start enteral nutrition in patients with shock requiring dobutamine or with SAPS II ≥ 62 and hemoglobin ≤ 10.9 g/dL; it is independently associated with AMI ^[58]B2b.
• Do NOT withhold anticoagulation for fear of bleeding; the evidence shows no increase in hemorrhagic complications ^[64]B3b.
• Do NOT delay revascularization for a trial of medical therapy alone, the window for bowel salvage is measured in hours, not days ^[10]A1c.

Controversies and Guideline Disagreement

Pearl: Initiate resuscitation, broad-spectrum antibiotics, and therapeutic-dose anticoagulation concurrently as soon as the diagnosis is suspected; delay in any of these three pillars independently worsens survival (NNT=8 for anticoagulation alone) ^[64]B3b.

Once resuscitation is underway, the surgeon must decide whether to operate, and if so, how urgently. This decision hinges on the likelihood of transmural bowel necrosis, the etiology of ischemia, and the patient's physiological reserve. The choice between operative and nonoperative management is the first and most consequential surgical decision node, and it must be made with the understanding that delays increase mortality while unnecessary laparotomy carries its own morbidity.

Indications for Operative Intervention

Absolute indications for immediate laparotomy include peritonitis on examination, pneumatosis intestinalis or portal venous gas on CT, and free intraperitoneal air. In the absence of these, the following independent predictors of transmural bowel necrosis should lower the threshold for surgery ^[17]C4:

• Mesenteric arterial occlusion (OR 26.5, p=0.02)
• Leukocytosis (OR 1.3 per unit, p<0.0001)
• Acidosis (OR 3.8, p=0.04)
• Free intraperitoneal fluid (OR 4.21, p=0.005)
• Combined portal vein and superior mesenteric vein thrombosis (OR 3.4, p=0.026)

In venous AMI, systemic anticoagulation (unfractionated heparin ) is first-line if no peritonitis; surgery is reserved for clinical deterioration or failure of medical therapy. In nonocclusive mesenteric ischemia (NOMI), medical management, optimizing cardiac output, avoiding vasopressors, and considering intra-arterial vasodilators, is the mainstay, but bedside laparoscopy can assess bowel viability and avoid non-therapeutic laparotomy in up to 45% of patients ^[37]C4.

Timing of Intervention

Time from symptom onset to revascularization is a critical modifiable factor. A 48-hour inflection point has been identified: patients revascularized >48 hours after symptom onset had significantly higher perioperative mortality (39% vs 14%) and short bowel syndrome (39% vs 12%, p=0.002) compared with those treated within 48 hours ^[34]B2b. Long-term mortality (HR 2.95), AMI recurrence (HR 6.36), and reintervention (HR 3.89) were also worse ^[34]B2b. Time delay to surgery was an independent predictor of perioperative mortality in a separate cohort (p=0.023) ^[28]B2b.

However, the AMESI substudy challenges a purely time-based paradigm: after adjusting for illness severity, treatment modality (endovascular vs surgical) had no independent effect on mortality, and no reliable thresholds for endovascular efficacy could be identified ^{[27]B2b[68]D5}. The decision should therefore integrate both time and the patient's physiological status. Revascularization within 48 hours is a target, not a guarantee, a patient in shock with peritonitis requires immediate laparotomy regardless of the clock.

Operative vs Nonoperative Choice by Etiology

Arterial occlusive AMI: Endovascular revascularization (EVR) is preferred as the first strategy when there is no peritonitis and no contraindication. A meta-analysis of 11 studies (1141 patients) found that EVR, compared with open surgical revascularization (OSR), did not reduce short-term mortality (OR 0.79) but was associated with decreased bowel resection (OR 0.42) and short bowel syndrome (OR 0.39) ^[1]A1a. Pooled mortality estimates from 39 studies were 26% for EVR, 40% for OSR, and 32% for retrograde open mesenteric stenting (ROMS) ^[70]B2a. The AMESI substudy reported a striking 2.9% mortality in the endovascular-effective group vs 45.8% in the surgical group, but this reflects selection bias, sicker patients underwent surgery ^[27]B2b. ROMS carries a 31.2% in-hospital mortality and a 26.3% stent-related complication rate at 30 days ^[35]B2b.

Venous AMI: Nonoperative management with anticoagulation is successful in most cases. Surgery is indicated for peritonitis, failure to improve, or when predictors of necrosis (combined PV/SMV thrombosis) are present ^[17]C4.

NOMI: Medical management is first-line. Laparoscopy or laparotomy is reserved for suspected necrosis. Bedside laparoscopy avoided non-therapeutic laparotomy in **9 of 20 ** NOMI patients, with a mortality of 11% in that group vs in those who required resection ^[37]C4.

Damage Control vs Primary Anastomosis

When resection is necessary, a damage control approach, resection, temporary abdominal closure, and second-look laparotomy at 48 hours, reduces anastomotic dehiscence (5.3% vs 23.4%, p=0.03) and need for ileostomy (2.6% vs 19.1%, p=0.03) compared with primary anastomosis in patients with limited ischemia ^[59]B2b. Open abdomen overall is associated with increased mortality (OR 1.58, 95% CI 1.38-1.81) except in revascularization patients, where no such association exists ^[38]B2b. One in 10 patients who underwent primary closure required reoperation ^[38]B2b. Thus, damage control should be used selectively, when bowel viability is uncertain, when a second look is planned, or when the patient is physiologically deranged.

Risk Stratification for Decision-Making

The NSQIP-based risk calculator for mortality after bowel resection for AMI (C statistic 0.84) incorporates preoperative DNR status, open wound, low albumin, dirty case, and poor functional status ^[30]B2b. Independent predictors of perioperative mortality include previous cardiac illness, elevated urea, and involvement of both small and large bowel; intestinal resection was protective (p<0.001) ^[28]B2b. These tools can inform shared decision-making, especially in elderly or frail patients.

Pearl: The decision to operate should be driven by the presence of peritonitis or strong predictors of transmural necrosis, not solely by time from symptom onset; however, once the decision is made, revascularization within 48 hours is associated with significantly better outcomes, aim for the window, but do not delay laparotomy in a deteriorating patient.

Once the decision to operate is made, the operative approach must be tailored to the patient's physiology, the etiology of ischemia, and the extent of bowel compromise. The choice between endovascular revascularization, open surgery, or a hybrid strategy hinges on the presence of peritoneal signs, the anatomic pattern of occlusion, and institutional resources. Perioperative optimization, aggressive resuscitation, timely antibiotics , and planned re-exploration, determines whether the patient tolerates the chosen operation.

Choice of Revascularization Technique

For acute superior mesenteric artery (SMA) occlusion, endovascular therapy (EVT) and open surgical revascularization (OS) yield comparable in-hospital mortality after adjustment for baseline severity. In the AMESI substudy, unadjusted mortality was 2.9% for effective endovascular treatment versus 45.8% for surgery, but multivariable analysis showed no independent effect of treatment modality (surgery OR 1.59) ^[27]B2b. A large Japanese registry (n=746) confirmed similar in-hospital mortality (EVT 22.5% vs OS 21.4%, p=0.72) and bowel resection rates (8.2% vs 8.5%) ^[80]C4. EVT was associated with a 6-day shorter hospital stay and lower costs ^[80]C4.

Patient selection drives outcomes. The surgical cohort in AMESI had higher lactate, C-reactive protein, and illness severity scores, reflecting selection bias toward sicker patients ^[27]B2b. The WSES guidelines recommend an endovascular-first approach for patients without peritonitis, reserving open surgery for those with peritoneal signs or failed endovascular attempts ^[9]A1c. However, no reliable thresholds for endovascular efficacy have been identified; the decision should be based on the patient's general condition and the cause of occlusion rather than time from symptom onset ^{[27]B2b[68]D5}.

Hybrid and open techniques remain essential. Retrograde open mesenteric stenting (ROMS) via a laparotomy allows simultaneous assessment of bowel viability and revascularization of an atherosclerotic SMA occlusion at its origin ^[71]D5. Surgical bypass (e.g., supraceliac aorto-SMA bypass) is seldom needed but may be required when endovascular access fails or extensive thrombosis precludes stenting ^[71]D5. For embolic occlusion, open embolectomy with a Fogarty catheter is effective and allows direct inspection of the bowel ^[10]A1c.

Local thrombolytic therapy can be combined with laparoscopy in selected patients without peritoneal signs. In a retrospective series, mortality was 20% (1/5) in patients without peritonitis versus 62.5% (5/8) in those with peritonitis ^[73]C4. This approach requires careful patient selection and close monitoring.

For mesenteric venous thrombosis (MVT), immediate systemic anticoagulation with unfractionated heparin or low-molecular-weight heparin is the cornerstone ^[74]B2a. Progression to peritonitis mandates laparotomy; frank transmural necrosis should be resected, and bowel anastomosis may be delayed until a second look ^[74]B2a. Endovascular options (transhepatic or transjugular thrombolysis) are reserved for patients who do not improve with anticoagulation alone but lack peritonitis ^[74]B2a.

Colon ischemia portends a worse prognosis. In a retrospective cohort, 30-day mortality was 49% with colon involvement versus 10% without (p<0.01), and short bowel syndrome occurred in 49% versus 19% ^[75]B3b. Emergent laparotomy was associated with shorter hospital stay and less short bowel syndrome compared with initial endovascular therapy ^[75]B3b.

Damage Control and the Open Abdomen

When bowel viability is uncertain after resection, a damage control approach with temporary abdominal closure and planned second-look laparotomy at 24-48 hours reduces anastomotic complications. In a prospective study of 85 patients with limited acute mesenteric ischemia, the damage control group had significantly lower anastomotic dehiscence (5.3% vs 23.4%; p=0.03; NNT=6) and need for ileostomy (2.6% vs 19.1%; p=0.03; NNT=7) compared with primary anastomosis ^[59]B2b. Mortality and overall morbidity did not differ between groups ^[59]B2b.

The open abdomen is associated with increased mortality (OR 1.58, 95% CI 1.38-1.81) and prolonged ventilation (OR 4.04) in the overall AMI population, but this association disappears in patients undergoing revascularization ^[38]B2b. Therefore, the open abdomen should be used selectively, primarily when bowel viability is in doubt, when a second look is planned, or when abdominal compartment syndrome is a concern ^{[38]B2b[59]B2b}. Approximately 10% of patients who undergo primary fascial closure require reoperation ^[38]B2b.

Role of Laparoscopy

Laparoscopy can avoid non-therapeutic laparotomy in patients with non-occlusive mesenteric ischemia (NOMI) or when the diagnosis is uncertain. In a series of 20 NOMI patients, bedside laparoscopy avoided laparotomy in 9 (45%), with a mortality of 11% in that subgroup ^[37]C4. No morbidity was attributed to the laparoscopic procedure ^[37]C4. A selective minimally invasive strategy, assigning patients to laparoscopy combined with endovascular therapy, endovascular therapy alone, or traditional laparotomy based on an algorithm, achieved a 30-day chronic intestinal failure-free survival of 71% and short-term mortality of 11.9% ^[78]C4. However, 43% of patients undergoing laparoscopic exploration required conversion to laparotomy ^[78]C4.

Perioperative Optimization

• Resuscitation: Lactate clearance and hemodynamic stability are prerequisites for any intervention. Balanced crystalloids are preferred; vasopressors should be minimized to avoid splanchnic vasoconstriction ^[9]A1c.
• Antibiotics: Broad-spectrum antibiotics covering enteric gram-negative and anaerobic organisms should be administered before incision ^[9]A1c.
• Anticoagulation: For arterial occlusion, systemic heparin is started after revascularization to prevent re-thrombosis, but the risk of bleeding must be weighed ^[10]A1c. For MVT, full-dose unfractionated heparin is given intraoperatively and continued postoperatively; the effect can be reversed with protamine sulfate if bleeding occurs ^[74]B2a. Transition to direct oral anticoagulants or vitamin K antagonists is guided by the underlying thrombophilia ^[74]B2a.
• Nutritional support: Early enteral nutrition via a nasojejunal tube distal to any anastomosis should be considered. Refeeding enteroclysis using the distal bowel after resection has been described as a technique to maintain gut integrity ^[77]C4.

Pearl: The key to operative success is not the choice of revascularization technique but the timing of intervention and the decision to leave the abdomen open for a planned second look when bowel viability is uncertain.

Controversies and Guideline Disagreement

The operative approach chosen carries its own spectrum of complications, which must be anticipated and managed systematically. Complications are best categorized by their origin, bowel ischemia, revascularization, or the open abdomen, and graded by the Clavien-Dindo classification to guide intervention and inform consent.

Complications of Bowel Ischemia and Resection

Short bowel syndrome (SBS) is the most consequential disease-specific complication. In the meta-analysis of arterial AMI, endovascular revascularization (EVR) was associated with a lower odds of SBS compared with open surgery (OR 0.39, 95%; very low certainty) ^[1]A1a. Delayed revascularization beyond 48 hours from symptom onset increased SBS rates from 12% to 39% ^[34]B2b. Management of SBS includes early parenteral nutrition, intestinal rehabilitation, and, in selected patients, surgical lengthening or intestinal transplantation. Anastomotic leak , though not separately reported in the reviewed studies, is inferred from the 10.8% reoperation rate among patients who underwent primary fascial closure ^[38]B2b. Abdominal compartment syndrome (ACS) occurred in 32% of patients undergoing damage control surgery (DCS) for non-traumatic emergencies, including AMI ^[16]C4; treatment is open abdomen with temporary closure.

Second-look laparotomy is a planned complication-driven procedure. Among NOMI patients treated with bedside laparoscopy, a second look 48 hours later revealed infarction recurrences in 4 of 11 resected patients (36%) and new necrosis in 5 of 9 non-resected patients (56%) ^[37]C4. This supports routine second-look in all patients, typically 24-48 hours after the index operation.

Complications of Revascularization

Stent-related complications after retrograde open mesenteric stenting (ROMS) occurred in 26.3% of patients within 30 days, including occlusion (n=7), residual dissection/thrombus (n=4), distal kinking (n=2), and stent migration (n=2) ^[35]B2b. These require reintervention: balloon angioplasty, repeat stenting, or conversion to open bypass. The 3-year freedom from stent-related reintervention was 68.2% (95% CI 50%-81%) ^[35]B2b. In endovascular treatment of acute superior mesenteric vein thrombosis, complications included hepatic artery bleeding (16.7%), hepatic arteriovenous fistula (8.3%), and melena (8.3%) ^[81]C4. Management is angiographic embolization or, if unsuccessful, surgical repair.

Complications of the Open Abdomen

Open abdomen (OA) after AMI laparotomy is associated with increased mortality (OR 1.58, 95% CI 1.38-1.81) and prolonged ventilation (OR 4.04, 95% CI 3.55-4.62) ^[38]B2b. However, in patients who underwent revascularization, this mortality association was not seen (P = 0.528), suggesting OA is a tool for specific cases, planned relaparotomy, impending ACS, or extensive bowel edema. Management includes temporary abdominal closure, aggressive fluid resuscitation, and early fascial closure when feasible.

Systemic Complications and Mortality

Overall 30-day morbidity after bowel resection for AMI is 56.6% and mortality 27.9% ^[30]B2b. In DCS series, mortality rises with number of DCS criteria: 24% with one criterion, 48% with two, and 62% with ≥3 (P < 0.001) ^[16]C4. Independent predictors of mortality include age (P = 0.018) and INR ≥1.7 (P = 0.001) ^[16]C4.

Management of Complications: A Structured Approach

• Abdominal sepsis / anastomotic leak: early re-laparotomy with washout, resection of non-viable bowel, and temporary abdominal closure. Antibiotics guided by intraoperative cultures.
• Stent occlusion: immediate angiographic evaluation; thrombectomy, balloon angioplasty, or re-stenting. If failed, open surgical revascularization.
• Short bowel syndrome: consult intestinal rehabilitation team; total parenteral nutrition via dedicated central line; consider teduglutide (if approved) or surgical lengthening.
• Abdominal compartment syndrome: measure intra-abdominal pressure; if >20 mmHg with organ dysfunction, decompress via open abdomen.

Pearl: The most devastating complications, short bowel syndrome, stent occlusion, and abdominal compartment syndrome, are best prevented by timely revascularization (within 48 hours) and by committing to a second-look laparotomy in all patients with extensive bowel ischemia; when complications occur, a structured approach with early reintervention and intestinal rehabilitation reduces long-term disability ^{[34]B2b[37]C4[38]B2b}.

The mortality of acute mesenteric ischemia has fallen from nearly 80% in the 1970s to approximately 44% in contemporary meta-analyses, driven by iterative advances in imaging, revascularization, and critical care ^{[94]C4[91]B2a}. This trajectory reflects a fundamental shift from a disease uniformly considered fatal to one with a definable window for salvage.

The Era of Late Diagnosis and Open Surgery

In the 1970s, diagnosis relied on clinical suspicion and plain radiography; mesenteric angiography was reserved for the few centers with dedicated expertise. Krausz and Manny reported a 77.5% mortality among 40 patients with acute superior mesenteric artery occlusion, emphasizing that “a high index of suspicion, aggressive measures for early diagnosis, and early operative treatment” were the only means to improve outcome ^[94]C4. Open surgical embolectomy or bypass was the standard, but outcomes were poor: Endean et al. in 2001 noted an overall survival of 52% compared with 25% in historical controls, yet survival for arterial embolism and thrombosis remained 41% and 38%, respectively ^[90]C4. The introduction of multidetector CT angiography in the 1990s transformed diagnosis, enabling rapid, noninvasive confirmation of AMI and its subtype ^{[88]A1c[92]C4}.

The Shift to Endovascular Therapy

Endovascular approaches began to challenge open surgery in the early 2000s. Johnston et al. demonstrated that mesenteric bypass grafts could achieve good early and late results, but also noted that complete revascularization of both the superior mesenteric artery and celiac artery and prograde bypass reduced the risk of late bowel ischemia ^[95]C4. The ACR Appropriateness Criteria in 2017 endorsed aspiration embolectomy, transcatheter thrombolysis , and angioplasty with or without stenting for acute arterial occlusion, while recommending transarterial vasodilator infusion (nitroglycerin, papaverine, glucagon, prostaglandin E1) for nonocclusive mesenteric ischemia ^[89]A1c. A 2024 comprehensive review confirmed a trend toward endovascular interventions due to apparent reduced mortality and complications, though the best primary treatment remains debated ^[96]D5.

The Emergence of Hybrid and Stroke Center Models

Newer literature suggests that hybrid approaches combining open and endovascular techniques, and the creation of intestinal stroke centers, may be superior to either strategy alone ^[96]D5. The NUTRIREA-2 post hoc analysis added a cautionary note: among critically ill ventilated patients with shock, enteral nutrition, dobutamine use, SAPS II ≥62, and hemoglobin ≤10.9 g/dL were independently associated with AMI, supporting a strategy of delayed or cautious enteral feeding in this population ^[58]B2b. Laparoscopy emerged as a tool to reduce non-therapeutic laparotomy in patients with nonocclusive mesenteric ischemia, with Cocorullo et al. reporting a mortality of 11% in the non-resected group compared with in those requiring resection ^[37]C4. The Society for Vascular Surgery guidelines for chronic mesenteric ischemia recommend endovascular revascularization with a balloon-expandable covered stent as initial therapy, with open repair reserved for select younger patients ^[72]A1c; this paradigm increasingly influences acute management as well.

Abandoned and Evolving Practices

Several historical practices have been abandoned or modified. Digoxin use, once common in patients with atrial fibrillation and AMI, has declined significantly ^[92]C4. Diagnostic angiography has been largely replaced by CT angiography, which is now the imaging modality of choice ^[88]A1c. The role of routine second-look laparotomy is being re-evaluated, with laparoscopy offering a less invasive alternative ^[37]C4. Systemic anticoagulation remains the cornerstone for mesenteric venous thrombosis , but endovascular thrombolysis and transjugular intrahepatic portosystemic shunt creation are increasingly employed for severe cases ^{[89]A1c[97]D5}.

The evolution of treatment for acute mesenteric ischemia reflects a gradual but meaningful improvement in outcomes, from mortality rates exceeding to contemporary survival approaching 50-60%. These gains set the stage for the prognostic factors and natural history discussed in the next section.

Pearl: The creation of intestinal stroke centers and hybrid strategies may further improve outcomes, but the optimal primary treatment is still debated ^[96]D5.

The preceding historical perspective underscores that despite decades of surgical and endovascular innovation, mortality from acute mesenteric ischemia (AMI) remains stubbornly high. Population-based data from Estonia report an overall hospital mortality of 64% and 1-year all-cause mortality of 74% ^[2]B2b. Among the 53% of patients who receive active treatment (revascularization and/or resection), hospital mortality falls to 32% and 1-year mortality to 51% ^[2]B2b. In 21% of cases, exploratory surgery reveals unsalvageable bowel, prompting end-of-life care; another 25% receive only palliative management ^[2]B2b. Without intervention, progression to intestinal necrosis and death is the rule, with historical mortality consistently reported at approximately 50% ^{[9]A1c[10]A1c}.

Overall Mortality by Subtype and Treatment

Mortality varies substantially by subtype and management strategy. After bowel resection for AMI, 30-day postoperative mortality is 27.9% (NSQIP data) ^[30]B2b; older series report perioperative mortality as high as 65.2% ^[28]B2b. In non-occlusive mesenteric ischemia (NOMI), overall mortality is 30%, but rises to 45.5% when resection is required ^[37]C4. Patients with NOMI who avoid laparotomy through prompt vasodilator therapy have mortality as low as 11% ^[37]C4. Endovascular treatment, when effective as monotherapy, carries a mortality of only 2.9%, but this reflects favorable patient selection; surgical mortality in the same study was 45.8% ^{[27]B2b[68]D5}. Multivariable analysis confirms that baseline illness severity, not treatment modality, independently drives mortality (surgery OR 1.59) ^[68]D5.

Prognostic Factors and Risk Stratification

Time from symptom onset to intervention is the most critical modifiable prognostic factor. An inflection point at 48 hours has been identified: revascularization beyond 48 hours is associated with higher perioperative mortality (39% vs 14%; absolute risk difference 25%; NNT = 4 to prevent one death if treated within 48 hours) and higher rates of short bowel syndrome (39% vs 12%) ^[34]B2b. Delay >24 hours also increases mortality (50% vs 27% for <12 hours) ^[100]C4.

Other independent predictors of mortality include age >70 years (median survival 9.5 months vs overall) ^[100]C4, preexisting cardiac illness, acute renal failure (creatinine >1.7 mg/dL), colonic involvement, shock, acidosis (pH <7.3), and elevated lactate ^{[28]B2b[99]C4[102]B2b}. The RADIAL score incorporates five variables, hypotension, age >65 years, pH <7.3, creatinine >1.7 mg/dL, and absence of rectal bleeding, to stratify in-hospital mortality risk into low (30-40%), intermediate (50-60%), and high (80%) categories (AUC 0.78) ^[102]B2b.

Radiologic findings also carry prognostic weight. Pneumatosis intestinalis on CT is associated with 30-day mortality (OR 2.42) ^[6]B3b. Historically, pneumatosis and portal venous gas signaled 70% mortality, but contemporary series report 31% overall; when ischemia is confirmed, mortality rises to 69% ^[42]B2a.

Recurrence and Long-Term Outcomes

AMI recurrence is strongly tied to treatment timing and etiology. Revascularization after 48 hours confers a 6-fold higher risk of recurrence (HR 6.36) and reintervention (HR 3.89) compared with earlier intervention ^[34]B2b. Thrombotic AMI carries higher recurrence (HR 5.97) and reintervention (HR 8.02) rates than embolic AMI ^[34]B2b. Long-term survival after retrograde open mesenteric stenting (ROMS) is 59.7% at 3 years, with primary patency of 81.3% ^[35]B2b. Cumulative survival after open surgery is 44.6% at a mean follow-up ^[100]C4. Stent-related complications occur in 26.3% of patients within 30 days ^[35]B2b.

Pearl: The single most actionable prognostic factor is time to revascularization, every hour beyond 48 hours from symptom onset increases the risk of bowel necrosis, short bowel syndrome, and death; a target of <12 hours from admission to intervention should drive institutional protocols.

The prognosis of acute mesenteric ischemia varies sharply across age, pregnancy, and immune status, each altering the diagnostic threshold, imaging choice, and risk-benefit calculus of intervention.

Pediatrics

Acute mesenteric ischemia in children is exceedingly rare, with no cases captured in the largest population-based study of adults aged 32-104 years ^[2]B2b. The few reports describe nonocclusive mesenteric ischemia (NOMI) triggered by systemic infections. In a 6‑year‑old with Mycoplasma pneumoniae pneumonia, NOMI led to intestinal necrosis without mesenteric vascular occlusion; diagnosis was delayed because vasospasm is invisible on standard imaging ^[32]C4. Pediatric AMI should be suspected when a septic child with abdominal pain has unexplained lactic acidosis or organ dysfunction. Multiphasic CT is the confirmatory test, but the risk of radiation must be weighed. Management follows the same principles, resuscitation, revascularization if feasible, and resection of nonviable bowel, but no age‑specific dose adjustments for anticoagulation or vasopressors are established.

Pregnancy

No cases of AMI in pregnancy were reported in the included studies. The diagnostic and therapeutic pathway must be modified to protect the fetus. Mesenteric CT angiography exposes the fetus to ionizing radiation; alternatives such as MRI with contrast or ultrasound are less validated but may be considered if the clinical suspicion is intermediate. When surgery is indicated, the gravid uterus complicates abdominal access and may increase the risk of preterm labor . The choice of revascularization and bowel resection should follow standard guidelines, with the addition of obstetric consultation. No maternal or fetal outcome data are available to guide specific drug dosing or delivery timing.

Elderly

Older patients dominate the AMI population. In a nationwide cohort of 577 patients, the median age was 79 years (range 32-104), 57% were female, and 81% had hypertension , 67% atherosclerosis, and 52% atrial fibrillation ^[2]B2b. Overall hospital mortality was 64% ^[2]B2b. Age was a significant univariate predictor of perioperative mortality (P = 0.01) but not an independent risk factor after adjustment for cardiac disease and renal failure ^[28]B2b. In a damage‑control surgery (DCS) series, age (P = 0.018) and INR ≥ 1.7 (P = 0.001) were independent predictors of mortality ^[16]C4. Mortality increased with the number of DCS criteria: 24% with one criterion, 48% with two, and 62% with three or more ^[16]C4.

Elderly patients often present with nonspecific pain, a higher rate of digoxin intake (a historical risk factor that has declined over time ^[92]C4), and greater delay to surgery. The 48‑hour revascularization threshold (mortality 39% vs. 14% when delayed >48 h) may be more difficult to meet in the elderly due to atypical presentation ^[34]B2b. Comorbidity interactions are critical: chronic kidney disease, hypoperfusion from cardiac failure, and the use of loop diuretics or digoxin exacerbate splanchnic vasoconstriction. Intestinal resection, when performed, is associated with lower mortality (protective in multivariate analysis ^[28]B2b), but the risk of short‑bowel syndrome is high. The surgeon’s deliberation should incorporate the patient’s functional status and goals of care, as institutional resources and concordant expectations influence the decision to operate ^[103]D5. A validated risk calculator (C‑statistic 0.84 for mortality) can inform preoperative counseling ^[30]B2b.

Immunocompromised

The provided literature does not include dedicated analyses of immunocompromised patients (e.g., transplant recipients, chemotherapy‑induced neutropenia, HIV/AIDS). These patients are at increased risk for NOMI from vasopressor use, sepsis, and fluid shifts, and for atypical thrombotic or infectious etiologies. Diagnostic vigilance must be high because fever and leukocytosis may be blunted. Management follows the same pathway as the general population, with attention to the underlying immunosuppression (e.g., holding immunosuppressive drugs perioperatively, providing antimicrobial prophylaxis). No studies have established specific dose modifications or thresholds.

Pearl: In elderly patients with AMI, the combination of age, cardiac disease, and renal failure portends a mortality exceeding 50%; the decision to operate should be guided by a validated risk calculator and a frank discussion of goals of care.

While pregnancy introduces unique hemodynamic and thrombotic considerations, the principles of prevention and surveillance apply across all populations at risk for mesenteric ischemia.

Primary Prevention

No randomized trials have evaluated primary prevention specifically for acute mesenteric ischemia (AMI). However, the strong association with atherosclerotic disease and hypercoagulable states informs risk-reduction strategies. For patients with diffuse atherosclerosis, aggressive modification of cardiovascular risk factors, smoking cessation, blood pressure control, lipid management , and diabetes optimization, likely reduces the progression of mesenteric occlusive disease ^[72]A1c. In patients with known mesenteric venous thrombosis (MVT) from a hypercoagulable state, indefinite anticoagulation with warfarin (target INR 2.0-3.0) or a direct oral anticoagulant prevents clot propagation and is associated with decreased recurrence and mortality ^[104]D5.

Secondary Prevention: Preventing Recurrence

After an episode of AMI, the risk of recurrence depends on the underlying etiology and the adequacy of revascularization.

• Anticoagulation: For MVT, anticoagulation is the cornerstone of secondary prevention. Lifelong therapy is often indicated if a persistent prothrombotic state is identified ^[104]D5.
• Antiplatelet therapy: After revascularization for atherosclerotic AMI or chronic mesenteric ischemia (CMI), single antiplatelet therapy (e.g., aspirin 81-325 mg daily) is typically prescribed, extrapolated from peripheral artery disease guidelines, though no specific trial has established its benefit in this population ^[72]A1c.
• Risk factor control: Continued smoking cessation, statin therapy (target LDL < 70 mg/dL), and antihypertensive management are recommended to slow progression of disease in untreated or contralateral mesenteric vessels ^[72]A1c.

Screening for Asymptomatic Mesenteric Stenosis

Routine screening of the general population for mesenteric artery stenosis is not recommended because of the low prevalence of asymptomatic disease and the potential for harm from unnecessary interventions. The Society for Vascular Surgery (SVS) guidelines suggest that surveillance imaging (computed tomography angiography or duplex ultrasound) may be considered for asymptomatic patients with severe mesenteric occlusive disease (e.g., >70% stenosis of the superior mesenteric artery) identified incidentally, particularly if they are undergoing major abdominal surgery that could compromise collateral flow ^[72]A1c. No class I recommendation exists for any screening program.

Post-Revascularization Surveillance

After revascularization for CMI or AMI, long-term surveillance with duplex ultrasound is recommended to detect restenosis before symptom recurrence. The SVS guidelines recommend surveillance at 6 months, 12 months, and annually thereafter ^[72]A1c. Duplex criteria for hemodynamically significant stenosis include a peak systolic velocity >330 cm/s and angiographic stenosis >60% ^[110]B2b.

Table: Recommended surveillance schedule after mesenteric revascularization ^{[72]A1c[110]B2b}

In a large multicenter series, 36% of patients developed mesenteric artery in-stent restenosis (MAISR) after a mean follow-up of 29 months ^[110]B2b. Among those with restenosis, 50% required reintervention because of symptom recurrence or progression to an asymptomatic preocclusive lesion ^[110]B2b. For CMI patients, endovascular revascularization was associated with higher rates of symptom recurrence compared with open bypass (29% vs 13%) and a faster onset of recurrence (median 64 days vs 338 days) ^[66]B3b. These data underscore the importance of close surveillance, particularly in the first year after endovascular therapy.

Reintervention for failing mesenteric reconstructions carries acceptable morbidity and mortality when performed electively. In patients with CMI treated by reoperative open repair or endovascular revascularization, early mortality was 0% and 0%, respectively, and freedom from symptom recurrence at 1 year was 88% and 83% ^[109]B2b. Covered stents may offer better patency than bare metal stents for the treatment of MAISR, though data are limited ^[110]B2b.

Patient Education

Patients should be educated about the symptoms of recurrent mesenteric ischemia: postprandial pain, food fear, weight loss, and diarrhea. They should be instructed to seek immediate evaluation for sudden severe abdominal pain, which could indicate progression to acute-on-chronic ischemia. Lifestyle modifications, including dietary adjustments and adherence to antiplatelet and statin therapy, should be reinforced at each visit.

Pearl: After revascularization for CMI, endoscopic surveillance appears less critical than duplex surveillance; the first year after endovascular intervention carries the highest risk of symptom recurrence, warranting a 6-month surveillance duplex to detect restenosis before it becomes symptomatic.